Treatment of community-acquired pneumonia

Chemotherapy

Volumn 46, Issue SUPPL. 1, 2000, Pages 24-31

  Bartlett, John ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolones; Guidelines; Infectious Disease Society of America (IDSA); Pneumonia, community acquired

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ALGORITHM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE SEVERITY; DRUG COST; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; LEGIONNAIRE DISEASE; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; SOCIAL ASPECT; SPUTUM CULTURE; THORAX RADIOGRAPHY;

EID: 0034059541     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000048489     Document Type: Conference Paper

References (12)

1. Bartlett JG, Breiman RF, Mandell LA, File TM Jr: Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998;26:811-838.
2. The World Health Report: 1997: Conquering suffering, enriching humanity. World Health Forum 1997; 18:248-260.
3. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
4. File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, Kojak C, Ruhin A: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997;41:1965-1792.
5. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, Segev S, Wijnands G: Treatment of community-acquired pneumonia: A randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995;8:1999-2007.
6. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, Weber GF, Petrillo MK, Houck PM, Fine JM: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-2084.
7. Gonzales R, Steiner JF, Lum A, Barren PH Jr: Decreasing antibiotic use in ambulatory practice. Impact of multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults. JAMA 1999;281:1512-1519.
8. Pallares R, Linares J, Vadillo M, Cabellos T, Manresa F, Viladrich PF, Martin R, Gudiol F: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995;333:474-480.
9. Pallares R: Treatment of pneumococcal pneumonia. Semin Respir Infect 1999;14:276-284.
10. Thornsberry C, Jones ME, Hickey ML, Mauriz Y, Kahn J, Sahm DF: Resistanee surveillance of Streptococcus pneumoniae. Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. J Antimicrob Chemother 1999;44:749-759.
11. Ramirez J, Unowsky J, Talbot GH, Zhang H, Townsend L: Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia. Clin Ther 1999;21:103-117.
12. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ: Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159: 2562-2572.